Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Polyagglutinability due to Hempas antigen]

H Rochant, A Gerbal

    Revue Francaise De Transfusion Et Immuno-Hematologie
    |March 1, 1976
    PubMed
    Summary
    This summary is machine-generated.

    A novel antigen, Hempas, was identified in congenital dyserythropoietic anemia type II. This discovery explains red blood cell agglutination and lysis in affected patients.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    [Characteristics of autoimmune hemolytic anemia in adults: retrospective analysis of 83 cases].

    La Revue de medecine interne·2002
    Same author

    [Autoimmune hemolytic anemia].

    La Revue du praticien·2002
    Same author

    Quinine improves results of intensive chemotherapy (IC) in myelodysplastic syndromes (MDS) expressing P-glycoprotein (PGP). Updated results of a randomized study. Groupe Français des Myélodysplasies (GFM) and Groupe GOELAMS.

    Advances in experimental medicine and biology·1999
    Same author

    A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes. Groupe Français des Myélodysplasies. Group Ouest-Est d'étude des Leucémies aiguës myéloïdes.

    Leukemia·1999
    Same author

    Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized study.

    British journal of haematology·1998
    Same author

    [Myelodysplastic syndromes: unusual and mild forms].

    Pathologie-biologie·1997

    Area of Science:

    • Hematology
    • Immunology
    • Genetics

    Context:

    • Congenital dyserythropoietic anemia type II (CDA II) is a rare inherited blood disorder.
    • Patients with CDA II exhibit unique red blood cell abnormalities.
    • A previously unrecognized antigen has been discovered on these red blood cells.

    Purpose:

    • To characterize a newly discovered antigen in patients with CDA II.
    • To investigate the serological and membrane properties associated with this antigen.
    • To understand the underlying mechanisms of red blood cell abnormalities in CDA II.

    Summary:

    • A new antigen, termed Hempas, has been identified in patients with congenital dyserythropoietic anemia type II (CDA II).
    • Hempas antigen is associated with hereditary erythroblastic multinuclearity and positive acidified serum test findings.

    Related Experiment Videos

  • Red blood cells expressing Hempas are agglutinated and lysed by a common IgM cold-reacting antibody, exhibiting reduced sialic acid and electrophoretic mobility, but enhanced agglutinability after enzyme treatment. I and i activity are increased.

    • Impact:

    • This discovery provides new insights into the pathophysiology of CDA II.
    • It may lead to improved diagnostic methods for CDA II.
    • Further research into Hempas antigen could elucidate the relationship between membrane abnormalities and nuclear division defects in erythroblasts.